Cited by 225Colorectal Cancer Treatments and StudiesLung Cancer Treatments and MutationsColorectal Cancer Surgical Treatments

The DOI matches its Crossref record; 90 of the 91 references it cites were found in a registry or an index.

Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives

Open access

Martinelli, E., Ciardiello, D., Martini, G., Troiani, T., Cardone, C., Vitiello, P.P., Normanno, N., Rachiglio, A.M., Maiello, E., Latiano, T., De Vita, F., Ciardiello, F.·2020·Annals of Oncology

DOI 10.1016/j.annonc.2019.10.007

Open this paper in CoChat — free account Open PDF

Abstract

Epidermal growth factor receptor (EGFR) inhibitors are valuable therapeutics in metastatic colorectal cancer (mCRC). Anti-EGFR monoclonal antibodies (MoAbs), such as cetuximab or panitumumab, in combination with chemotherapy are effective treatment options for patients with RAS and BRAF wild-type mCRC. Nevertheless, several issues are still open concerning the optimal use of anti-EGFR drugs in the continuum of care of mCRC. Novel approaches for increasing the efficacy of anti-EGFR therapies include better molecular selection of EGFR-dependent mCRC, intensification of chemotherapy, combination of anti-EGFR MoAbs and immune checkpoint inhibitors, and reintroduction of EGFR blockade or 'rechallenge' in selected patients who have previously responded to anti-EGFR MoAb therapy. An extensive translational research program was conducted in the Cetuximab After Progression in KRAS wIld-type colorectal cancer patients-Gruppo Oncologico dell' Italia Meridionale (CAPRI-GOIM) study with the aims of determining which subgroups of patients could benefit from the continuous inhibition of EGFR, from evaluating the role of liquid biopsy-based and its concordance with tissue-based molecular testing, and from investigating novel potential mechanisms of resistance to anti-EGFR therapies. In this review, we summarize the translational and clinical findings of the CAPRI-GOIM program in the context of the current knowledge of therapeutic strategies and of ongoing research on more appropriate uses of anti-EGFR therapies in RAS and BRAF wild-type mCRC patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2019.10.007

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Tumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Self-citation
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citation
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,095
Self-citation
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Self-citation
FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First-Line Treatment for Patients with Metastatic Colorectal Cancer (FIRE-3): A Randomised, Open-Label, Phase 3 Trial
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients with Metastatic Colorectal Cancer Previously Treated with an Oxaliplatin-Based Regimen
Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402
Eph receptors and ephrins in cancer: bidirectional signalling and beyond
Pasquale, E. B. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2806 · Cited by 1,216

Show all 91 references

Sorted by citations

Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now?
Stefani, C., Miricescu, D., Stanescu-Spinu, I.-I., Nica, R. I., Greabu, M., Totan, A. R., & Jinga, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910260 · Cited by 402
Molecular epidemiology and diagnostics of KRAS mutations in human cancer
Timar, J., & Kashofer, K. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09915-5 · Cited by 334
Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246
Precision oncology in metastatic colorectal cancer — from biology to medicine
Nicolantonio, F. D., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J. M., Trusolino, L., Bernards, R., & Bardelli, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00495-z · Cited by 240
Self-citation
Exosomal targeting and its potential clinical application
He, J., Ren, W., Wang, W., Han, W., Jiang, L., Zhang, D., & Guo, M. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01087-1 · Cited by 210
Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review)
Ahmad, R., Singh, J. K., Wunnava, A., Al-Obeed, O. A., Abdulla, M., & Srivastava, S. K. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4847 · Cited by 265
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer
Martinelli, E., Martini, G., Famiglietti, V., Troiani, T., Napolitano, S., Pietrantonio, F., Ciardiello, D., Terminiello, M., Borrelli, C., Vitiello, P. P., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2915 · Cited by 187
Self-citation
Artificial intelligence in the diagnosis and management of colorectal cancer liver metastases
Rompianesi, G., Pegoraro, F., Ceresa, C. D. L., Montalti, R., & TROISI, R. I. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i1.108 · Cited by 138
Advancements in combining targeted therapy and immunotherapy for colorectal cancer
Singh, M., Morris, V. K., Bandey, I. N., Hong, D. S., & Kopetz, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.05.001 · Cited by 139
Carboranes as unique pharmacophores in antitumor medicinal chemistry
Chen, Y., Du, F., Tang, L., Xu, J., Zhao, Y., Wu, X., Li, M., Shen, J., Wen, Q., Cho, C. H., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.01.005 · Cited by 124
Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer
Feng, J., Hu, Z., Xia, X., Liu, X., Lian, Z., Wang, H., Wang, L., Wang, C., Zhang, X., & Pang, X. (2023) · Oncogene · doi:10.1038/s41388-023-02676-9 · Cited by 95
Receptor-Targeted Nanomedicine for Cancer Therapy
Prajapati, A., Rangra, S., Patil, R., Desai, N., Jyothi, V. G. S. S., Salave, S., Amate, P., Benival, D. M., & Kommineni, N. (2024) · Receptors · doi:10.3390/receptors3030016 · Cited by 100
Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations
Chen, X., Chen, L., Peng, X., Deng, L., Wang, Y., Li, J.-J., Guo, D., & Niu, X. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101851 · Cited by 80
METTL14 modulates glycolysis to inhibit colorectal tumorigenesis in p53‐wild‐type cells
Hou, Y., Zhang, X., Yao, H., Hou, L., Zhang, Q., Tao, E., Zhu, X., Jiang, S., Ren, Y., Hong, X., et al. (2023) · EMBO Reports · doi:10.15252/embr.202256325 · Cited by 69
Structure–Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017–Present)
Șandor, A., Ionuţ, I. A., Marc, G., Oniga, I., Eniu, D. T., & Oniga, O. (2023) · Pharmaceuticals · doi:10.3390/ph16040534 · Cited by 79
Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond
Bitar, S. A., El-Sabban, M. E., Doughan, S., & Abou-Kheir, W. G. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i9.1395 · Cited by 69
Proteomics of post-translational modifications in colorectal cancer: Discovery of new biomarkers
Zhu, G., Jin, L., Sun, W., Wang, S., & Liu, N. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188735 · Cited by 63
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer
Ciardiello, D., Martinelli, E., Troiani, T., Mauri, G., Rossini, D., Martini, G., Napolitano, S., Famiglietti, V., Tufo, S. D., Masi, G., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.5635 · Cited by 64
Self-citation
Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer
Napolitano, S., Falco, V. D., Martini, G., Ciardiello, D., Martinelli, E., Corte, C. M. D., Esposito, L., Famiglietti, V., Liello, A. D., Avallone, A., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.0655 · Cited by 60
Self-citation
Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge
Marmorino, F., Boccaccino, A., Germani, M. M., Falcone, A., & Cremolini, C. (2020) · Cancers · doi:10.3390/cancers12082317 · Cited by 57
Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments
Tang, Y., Li, D., Duan, J.-Y., Sheng, L., & Wang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i6.926 · Cited by 58
ALYREF-mediated RNA 5-Methylcytosine modification Promotes Hepatocellular Carcinoma Progression Via Stabilizing EGFR mRNA and pSTAT3 activation
Nulali, J., Zhang, K., Long, M., Wan, Y., Liu, Y., Zhang, Q., Yang, L., Hao, J., Yang, L., & Song, H. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.82316 · Cited by 59
Electrochemical biosensors for measurement of colorectal cancer biomarkers
Zhang, W., Xiao, G., Chen, J., Wang, L., Hu, Q., Wu, J., Zhang, W., Song, M., Qiao, J., & Xu, C. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03197-8 · Cited by 53
Molecular Targets for the Treatment of Metastatic Colorectal Cancer
Cohen, R., Pudlarz, T., Delattre, J.-F., Colle, R., & André, T. (2020) · Cancers · doi:10.3390/cancers12092350 · Cited by 49
Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment
Wang, F., Huang, Y., Wu, H., Wang, Z., Jin, Y., Yao, Y.-C., Chen, Y., Zhao, Q., Chen, S., He, M.-M., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324852 · Cited by 51
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer
Bourhis, J., Stein, A., Paul de Boer, J., Van Den Eynde, M., Gold, K. A., Stintzing, S., Becker, J. C., Moran, M., Schroeder, A., Pennock, G., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102172 · Cited by 47
Self-citation
Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer
Fasano, M., Corte, C. M. D., Liello, R. D., Barra, G., Sparano, F., Viscardi, G., Iacovino, M. L., Paragliola, F., Famiglietti, V., Ciaramella, V., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000753 · Cited by 46
Self-citation
Colitis-associated carcinogenesis: crosstalk between tumors, immune cells and gut microbiota
Li, J., Ji, Y., Chen, N., Dai, L., & Deng, H. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01139-8 · Cited by 46
Quinazolinones as Potential Anticancer Agents: Synthesis and Action Mechanisms
Deng, Z., Li, J., Zhu, P., Wang, J., Kong, Y., Hu, Y., Cai, J., & Dong, C. (2025) · Biomolecules · doi:10.3390/biom15020210 · Cited by 45
Application of phototherapeutic-based nanoparticles in colorectal cancer
Yan, J., Wang, C., Jiang, X., Wei, Y., Wang, Q., Cui, K., Xu, X. L., Wang, F., & Zhang, L. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.58773 · Cited by 43
Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road
Ríos-Hoyo, A., Monzonís, X., Vidal, J., Linares, J., & Montagut, C. O. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1398419 · Cited by 41
Palmitoyltransferase ZDHHC6 promotes colon tumorigenesis by targeting PPARγ-driven lipid biosynthesis via regulating lipidome metabolic reprogramming
Shan, J., Li, X., Sun, R., Yao, Y., Sun, Y., Kuang, Q., Dai, X., & Sun, Y. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03154-0 · Cited by 37
Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes
Bekaii-Saab, T. S., Lach, K., Hsu, L.-I., Siadak, M., Stecher, M., Ward, J., Beckerman, R., & Strickler, J. H. (2023) · The Oncologist · doi:10.1093/oncolo/oyad200 · Cited by 36
Panitumumab plus trifluridine/tipiracil as anti‐ EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial
Napolitano, S., Ciardiello, D., Falco, V. D., Martini, G., Martinelli, E., Corte, C. M. D., Esposito, L., Famiglietti, V., Liello, A. D., Avallone, A., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34632 · Cited by 38
Self-citation
Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
Patelli, G., Vaghi, C., Tosi, F., Mauri, G., Amatu, A., Massihnia, D., Ghezzi, S., Bonazzina, E. F., Bencardino, K. B., Cerea, G., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00795-5 · Cited by 39
Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
Ciardiello, D., Martini, G., Famiglietti, V., Napolitano, S., Falco, V. D., Troiani, T., Latiano, T. P., Ros, J., Élez, E., Vitiello, P. P., et al. (2021) · Cancers · doi:10.3390/cancers13081941 · Cited by 36
Self-citation
Combination of long-acting TRAIL and tumor cell-targeted photodynamic therapy as a novel strategy to overcome chemotherapeutic multidrug resistance and TRAIL resistance of colorectal cancer
She, T., Shi, Q., Zhao, L., Feng, Y., Yang, H., Tao, Z., Li, H., Chen, J., Wang, S., Liang, Y., et al. (2021) · Theranostics · doi:10.7150/thno.51193 · Cited by 33
Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the Treatment of Cancer: A Review
Unnisa, A., Chettupalli, A. K., Hussain, T., & Kamal, M. A. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220408090541 · Cited by 32
Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance
Leite, L. F., Noronha, M. M., de Menezes, J. S. A., da Conceição, L. D., Almeida, L. F. C., Cappellaro, A. P., Belotto, M., Biachi de Castria, T., Peixoto, R. D., & Megid, T. B. C. (2025) · Cancers · doi:10.3390/cancers17172804 · Cited by 32
NT5DC2 knockdown inhibits colorectal carcinoma progression by repressing metastasis, angiogenesis and tumor-associated macrophage recruitment: A mechanism involving VEGF signaling
Zhu, Z., Hou, Q., & Guo, H. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112311 · Cited by 29
Cooperation between Prostaglandin E2 and Epidermal Growth Factor Receptor in Cancer Progression: A Dual Target for Cancer Therapy
Finetti, F., Paradisi, L., Bernardi, C., Pannini, M., & Trabalzini, L. (2023) · Cancers · doi:10.3390/cancers15082374 · Cited by 30
EphA2 and EGFR: Friends in Life, Partners in Crime. Can EphA2 Be a Predictive Biomarker of Response to Anti-EGFR Agents?
Cioce, M., & Fazio, V. M. (2021) · Cancers · doi:10.3390/cancers13040700 · Cited by 31
Construction and Analysis of a Colorectal Cancer Prognostic Model Based on N6-Methyladenosine-Related lncRNAs
Zeng, H., Xu, Y., Xu, S., Jin, L., Shen, Y., Rajan, K. C., Bhandari, A., & Xia, E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.698388 · Cited by 28
Machine learning and radiomics analysis by computed tomography in colorectal liver metastases patients for RAS mutational status prediction
Granata, V., Fusco, R., Setola, S. V., Brunese, M. C., Mauro, A. D., Avallone, A., Ottaiano, A., Normanno, N., Petrillo, A., & Izzo, F. (2024) · La radiologia medica · doi:10.1007/s11547-024-01828-5 · Cited by 27
Self-citation
True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature
Nicolazzo, C., Barault, L., Caponnetto, S., Renzi, G. D., Belardinilli, F., Bottillo, I., Bargiacchi, S., Macagno, M., Grammatico, P., Giannini, G., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.014 · Cited by 27
Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma
Román, M. S., Torres-Jiménez, J., Pozas, J., Esteban-Villarrubia, J., Albarrán, V., Ballesteros, P. Á., Chamorro-Pérez, J., Rodriguez, D. I. R., Orejana, I., Martínez-Delfrade, Í., et al. (2023) · Cancers · doi:10.3390/cancers15030863 · Cited by 29
Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival
Ciardiello, D., Famiglietti, V., Napolitano, S., Esposito, L., Pietrantonio, F., Avallone, A., Maiello, E., Cremolini, C., Troiani, T., Martinelli, E., et al. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.01.005 · Cited by 27
Self-citation
Exosomal Components and Modulators in Colorectal Cancer: Novel Diagnosis and Prognosis Biomarkers
Chang, Y., Chan, M., Li, C., Fang, C., Hsiao, M., & Chen, C. (2021) · Biomedicines · doi:10.3390/biomedicines9080931 · Cited by 25
Molecular testing for colorectal cancer: Clinical applications
Имянитов, Е. Н., & Kuligina, E. S. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i10.1288 · Cited by 26
Cell Growth Stimulation, Cell Cycle Alternation, and Anti-Apoptosis Effects of Bovine Bone Collagen Hydrolysates Derived Peptides on MC3T3-E1 Cells Ex Vivo
Wang, J., Liu, J., & Guo, Y. (2020) · Molecules · doi:10.3390/molecules25102305 · Cited by 23
Lymph Node Mapping for Tumor Micrometastasis
Han, M., Kang, R., & Zhang, C. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00111 · Cited by 24
E26 transformation-specific transcription variant 5 in development and cancer: modification, regulation and function
Wei, Y., Han, S., Wen, J., Liao, J., Liang, J., Yu, J., Chen, X., Xiang, S., Huang, Z., & Zhang, B. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00909-3 · Cited by 25
Exploring Potential Epigenetic Biomarkers for Colorectal Cancer Metastasis
Ajithkumar, P., Vasantharajan, S. S., Pattison, S. T., McCall, J. L., Rodger, E. J., & Chatterjee, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020874 · Cited by 22
The Protective Role of Decorin in Hepatic Metastasis of Colorectal Carcinoma
Reszegi, A., Horváth, Z., Karászi, K., Regős, E., Postniková, V., Tátrai, P., Kiss, A., Schaff, Z., Kovalszky, I., & Baghy, K. (2020) · Biomolecules · doi:10.3390/biom10081199 · Cited by 22
Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study
Parisi, A., Cortellini, A., Cannita, K., Venditti, O., Camarda, F., Calegari, M. A., Salvatore, L., Tortora, G., Rossini, D., Germani, M. M., et al. (2020) · Cancers · doi:10.3390/cancers12051259 · Cited by 21
Self-citation
The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis
Pereira, P. L., Iezzi, R., Manfredi, R. M., Carchesio, F., Bánsághi, Z., Brountzos, Ε., Spiliοpoulos, S., Echevarría-Uraga, J. J., Gonçalves, B., Inchingolo, R., et al. (2020) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-020-02646-8 · Cited by 21
Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
Cremolini, C., Montagut, C. O., Ronga, P., Venturini, F., Yamaguchi, K., Stintzing, S., & Sobrero, A. F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.946850 · Cited by 22
KRAS/NRAS Mutations Associated with Distant Metastasis and BRAF/PIK3CA Mutations Associated with Poor Tumor Differentiation in Colorectal Cancer
Zeng, J., Fan, W., Li, J., Wu, G., & Wu, H. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s428580 · Cited by 21
The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review
Ciardiello, D., Mauri, G., Bianchi, A. S., Siena, S., Zampino, M. G., Fazio, N., & Cervantes, A. M. R. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102683 · Cited by 23
Self-citation
Spatial-Frequency dual-branch attention model for determining KRAS mutation status in colorectal cancer with T2-weighted MRI
Ma, Y., Wang, J., Song, K., Qiang, Y., Jiao, X., & Zhao, J. (2021) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2021.106311 · Cited by 20
Dynamic Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer
Urbini, M., Marisi, G., Azzali, I., Bartolini, G., Chiadini, E., Capelli, L., Tedaldi, G., Angeli, D., Canale, M., Molinari, C., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00694 · Cited by 20
Pterostilbene inhibits gallbladder cancer progression by suppressing the PI3K/Akt pathway
Tong, C., Wang, Y., Li, J., Cen, W., Zhang, W., Zhu, Z., Yu, J., & Lu, B. (2021) · Scientific Reports · doi:10.1038/s41598-021-83924-4 · Cited by 20
Adverse Renal Effects of Anticancer Immunotherapy: A Review
Borówka, M., Łącki-Zynzeling, S., Nicze, M., Kozak, S., & Chudek, J. T. (2022) · Cancers · doi:10.3390/cancers14174086 · Cited by 20
EGFR-targeted hybrid lipid nanoparticles for chemo-photothermal therapy against colorectal cancer cells
Fang, F., Zhang, X., Tang, J., Wang, Y., Xu, J., & Sun, Y. (2023) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2023.105280 · Cited by 20
Machine learning-based radiomics analysis in predicting RAS mutational status using magnetic resonance imaging
Granata, V., Fusco, R., Brunese, M. C., Mauro, A. D., Avallone, A., Ottaiano, A., Izzo, F., Normanno, N., & Petrillo, A. (2024) · La radiologia medica · doi:10.1007/s11547-024-01779-x · Cited by 18
Self-citation
The power of heteronemin in cancers
Wang, K., Chen, Y., Yang, Y. S. H., Huang, H., Lee, S., Shih, Y.-J., Li, Z., Whang‐Peng, J., Lin, H., & Davis, P. J. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00816-z · Cited by 18
Publication trends and hotspots of drug resistance in colorectal cancer during 2002-2021: A bibliometric and visualized analysis
Zhao, P., Jiao, Y.-N., Ma, Z.-F., Yang, Y., Li, Y., Hu, S.-D., Li, S.-Y., & Du, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.947658 · Cited by 17
Exosomes derived from MDR cells induce cetuximab resistance in CRC via PI3K/AKT signaling‑mediated Sox2 and PD‑L1 expression
Wei, Z., Wang, Z., Chai, Q., Li, Z., Zhang, M., Zhang, Y., Zhang, L., Tang, Q., Zhu, H., & Sui, H. X. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11785 · Cited by 16
Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA : Individual patient data pooled analysis of CRICKET and CAVE trials
Martini, G., Ciardiello, D., Famiglietti, V., Rossini, D., Antoniotti, C., Troiani, T., Napolitano, S., Esposito, L., Latiano, T. P., Maiello, E., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5699 · Cited by 15
Self-citation
The role of artificial intelligence and image processing in the diagnosis, treatment, and prognosis of liver cancer: a narrative-review
Dimopoulos, P. M., Mulita, A., Antzoulas, A., Bodard, S., Leivaditis, V., Ακρίδα, Ι., Benetatos, N., Katsanos, K., Anagnostopoulos, C., & Mulita, F. (2024) · Gastroenterology Review · doi:10.5114/pg.2024.143147 · Cited by 18
Clonality and timing of relapsing colorectal cancer metastasis revealed through whole-genome single-cell sequencing
Alves, J. M., Prado‐Lòpez, S., Tomás, L., Valecha, M. V., Estévez‐Gómez, N., Alvariño, P., Geisel, D., Modest, D. P., Sauer, I. M., Pratschke, J., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215767 · Cited by 15
Safety and effectiveness of CIMAvax-EGF administered in community polyclinics
Carrodeguas, R. A. O., Monteagudo, G. L., Guerra, P. P., Montané, I. Á., Salomón, E. E., Lobaina-Lambert, L., Sosa, K. C., Pino, R. B., Mustelier, P. B., Rodríguez, E. V., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1287902 · Cited by 15
Advances in tumor vascular growth inhibition
Zhang, K., Shi, Y., Jin, Z., & He, J. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03432-5 · Cited by 15
Emerging magic bullet: subcellular organelle-targeted cancer therapy
Yan, Y., Zhang, Y., Liu, J., Chen, B., & Wang, Y. (2024) · Medical Review · doi:10.1515/mr-2024-0044 · Cited by 14
Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis
McCoy, M., Wolf, S., Struck, V., Thomas, N., Husmann, G., Zeuzem, S., Koch, C., Trojan, J., Schnitzbauer, A. A., Bechstein, W. O., et al. (2022) · Cancers · doi:10.3390/cancers14071641 · Cited by 14
Evaluation of antiproliferative agents using a cell-culture model.
Senderoff, R. I., Weber, P. A., Smith, D. R., & Sokoloski, T. D. (1990) · PubMed · Cited by 14
Engineering aptamer-directed phosphatase recruiting chimeras: a strategy for modulating receptor function and overcoming drug resistance
Zhou, Z., Liu, Y., Wang, Y., Jiang, H., Chen, T., Zhu, Y., Fu, T., & Li, J. (2025) · Nature Communications · doi:10.1038/s41467-025-59098-2 · Cited by 13
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)
Hajjo, R., Sabbah, D. A., Bardaweel, S. K., & Zhong, H. A. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2327307 · Cited by 13
Precision medicine in colorectal cancer: genomics profiling and targeted treatment
Muhar, A. M., Velaro, A. J., Prananda, A. T., Nugraha, S. E., Halim, P., & Syahputra, R. A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1532971 · Cited by 13
Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial
Ciardiello, D., Bielo, L. B., Napolitano, S., Latiano, T., Stefano, A. D., Tamburini, E., Toma, I., Bordonaro, R., RUSSO, A. E., Pisconti, S., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.104511 · Cited by 13
Self-citation
Vandetanib inhibits cell growth in EGFR-expressing cutaneous squamous cell carcinoma
Kitamura, S., Maeda, T., & Yanagi, T. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.07.111 · Cited by 13
Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial
Ciardiello, D., Bielo, L. B., Pietrantonio, F., Martini, G., Troiani, T., Martinelli, E., Natangelo, S., Bosco, M. F., Pisconti, S., Nisi, C., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105491 · Cited by 12
Self-citation
Kinectin1 depletion promotes EGFR degradation via the ubiquitin-proteosome system in cutaneous squamous cell carcinoma
Ma, J., Ma, S., Zhang, Y., Shen, Y., Huang, L., Lu, T., Wang, L., Wen, Y., & Ding, Z. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04276-5 · Cited by 12
Surface engineering of nanoparticles for imparting multifunctionality
Choudhury, H., Gorain, B., Pandey, M., Nirmal, J., & Kesharwani, P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820757-4.00001-6 · Cited by 12
Structure-based peptide ligand design for improved epidermal growth factor receptor targeted gene delivery
Decker, S., Taschauer, A., Geppl, E., Pirhofer, V., Schauer, M., Pöschl, S., Kopp, F. B., Richter, L., Ecker, G. F., Sami, H., et al. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.05.004 · Cited by 12
High sensitivity and rapid detection of KRAS and BRAF gene mutations in colorectal cancer using YbTixOy electrolyte-insulator-semiconductor biosensors
Pan, T.-M., & Liao, P.-Y. (2022) · Materials Today Chemistry · doi:10.1016/j.mtchem.2022.100979 · Cited by 12
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)
Ciardiello, D., Chiarazzo, C., Famiglietti, V., Damato, A., Pinto, C., Zampino, M. G., Castellano, G., Gervaso, L., Zaniboni, A., Oneda, E., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100567 · Cited by 13
Self-citation
Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry
Chong, L. C., Hardingham, J. E., Townsend, A. R., Piantadosi, C., Rico, G. T., Karapetis, C. S., Padbury, R., Maddern, G. J., Roy, A. C., & Price, T. J. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00760-8 · Cited by 12
EGFR targeting enhances the efficiency of chemotherapy through inhibiting IRE1α-XBP1s pathway in colorectal cancer cells
Huo, M., Zhao, Y., Liu, X., Gao, Y., Zhang, D., Chang, M., Liu, M., Xu, N., & Zhu, H. (2020) · Journal of Cancer · doi:10.7150/jca.44234 · Cited by 11
Heteronemin and Tetrac Induce Anti-Proliferation by Blocking EGFR-Mediated Signaling in Colorectal Cancer Cells
Unson, S., Chang, T., Yang, Y., Wang, S., Huang, C., Crawford, D. R., Huang, H., Li, Z., Lin, H., Whang‐Peng, J., et al. (2022) · Marine Drugs · doi:10.3390/md20080482 · Cited by 11
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials
Ciardiello, D., Napolitano, S., Famiglietti, V., Esposito, L., Falco, V. D., Liello, A. D., Avallone, A., Maiello, E., Pietrantonio, F., Cremolini, C., et al. (2023) · Cancers · doi:10.3390/cancers15072117 · Cited by 11
Self-citation
MCM5 is an oncogene of colon adenocarcinoma and promotes progression through cell cycle control
Mao, J., Shen, J. F., Lu, X., Cai, Y., Tao, R., Deng, Y., Zhang, Y., Wu, Y. K., & Chen, W. (2023) · Acta Histochemica · doi:10.1016/j.acthis.2023.152072 · Cited by 12
Network Toxicology and Molecular Docking to Elucidate the Mechanisms of Intestinal Toxicity Induced by P-Phenylenediamine Antioxidants and Their Quinone Derivatives
Zou, H., Tan, Y., Ren, X., Zhu, L., & Liu, Y. (2025) · Toxics · doi:10.3390/toxics13060480 · Cited by 10
Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
Ciardiello, D., Famiglietti, V., Napolitano, S., Esposito, L., Normanno, N., Avallone, A., Latiano, T. P., Maiello, E., Pietrantonio, F., Cremolini, C., et al. (2021) · Cancers · doi:10.3390/cancers13225715 · Cited by 11
Self-citation
Molecular basis and clinical application of targeted therapy in oncology
Tilak, T., Patel, A. K., & Kapoor, A. (2023) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2023.02.001 · Cited by 13
A prognostic four-gene signature and a therapeutic strategy for hepatocellular carcinoma: Construction and analysis of a circRNA-mediated competing endogenous RNA network
Zhang, H., Zhu, J., Liu, Z., Zhang, Y., Chen, J., & Chen, K. (2023) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2023.06.009 · Cited by 10
Novel heavily fucosylated glycans as a promising therapeutic target in colorectal cancer
Tsai, K., Chang, Y., Huang, C., Prince, G. M. S. H., Chen, H., Makondi, P. T., Shen, Y.-R., & Wei, P. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04363-5 · Cited by 10
Liposomes Loaded with the Proteasome Inhibitor Z-Leucinyl-Leucinyl-Norleucinal Are Effective in Inducing Apoptosis in Colorectal Cancer Cell Lines
Cortese, K., Marconi, S., Aiello, C., Gagliani, M. C., Pilato, S., Zappacosta, R., Fontana, A., & Castagnola, P. (2020) · Membranes · doi:10.3390/membranes10050091 · Cited by 10
RNF141 interacts with KRAS to promote colorectal cancer progression
Zhang, J., Jiang, X., Yin, J., Dou, S., Xie, X., Liu, T., Wang, Y., Wang, S., Zhou, X., Zhang, D., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01877-4 · Cited by 10
Circular RNA circWBSCR22 facilitates colorectal cancer metastasis by enhancing CHD4's protein stability
Luo, J., Xu, S., Wang, J., He, L., & Li, Z. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.137135 · Cited by 9

Authors: Martinelli, E., Ciardiello, D., Martini, G., Troiani, T., Cardone, C., Vitiello, P. P., Normanno, N., Rachiglio, A. M., Maiello, E., Latiano, T., De Vita, F., & Ciardiello, F.
Affiliations: University of Campania "Luigi Vanvitelli" (IT)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
Casa Sollievo della Sofferenza (IT)
Corresponding author: Ciardiello, F.
ORCID: Ciardiello, D.
Martini, G.
Troiani, T.
Cardone, C.
Vitiello, P.P.
Normanno, N.
Rachiglio, A.M.
Maiello, E.
Ciardiello, F.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2020-01
Volume: 31
Issue: 1
Pages: 30-40
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1016/j.annonc.2019.10.007
OpenAlex: W2999771324
Cited by: 225
References: 91
Citations by year: 2026: 11 · 2025: 25 · 2024: 32 · 2023: 42 · 2022: 66 · 2021: 32 · 2020: 16
FWCI: 4.19
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 85 d)
Locations: Annals of Oncology (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
Funders: Associazione Italiana per la Ricerca sul Cancro
Regione Campania
Sanofi
Amgen
Merck KgA
Roche
Servier
Bayer
Array
MSD
BMS
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords: EGFR inhibitors, metastatic colorectal cancer, cetuximab, panitumumab, RAS wild-type, BRAF wild-type, drug rechallenge, immune checkpoint inhibitors, liquid biopsy, resistance mechanisms, molecular selection, chemotherapy intensification
MeSH terms: Cetuximab, Panitumumab, Antineoplastic Agents, Humans, Mutation, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks